Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:51:38.169Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:51:38.169Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe223a2c9097866a428bc5ebda2476775355ce68fd4daeb413d6e89482dd9b46
FORWARD PE RATIO
N/A
GlucoTrack, Inc.
Market Cap
$901902.00
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GlucoTrack, Inc. (GCTK) | $901902.00 | N/A |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | N/A |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A |
| CDT Equity Inc. (CDT)vs › | $716854.00 | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
